NexImmune, Inc. (NEXI)

0,2096 +0,0102 (+5,12%) Börsenschluss: 03:59PM EDT

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 50

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Kristi Jones R.Ph.	CEO, Pres & Director	680,44k	N/A	1963
Dr. Mathias Oelke Ph.D.	Chief Scientific Officer	621,26k	N/A	1969
Mr. John Trainer M.B.A.	Consultant	546,13k	N/A	1974
Dr. Jerome Bernard Zeldis M.D., Ph.D.	Consultant	618,2k	N/A	1950
Mr. Timothy Stover	VP, Corp. Controller and Principal Financial & Accounting Officer	N/A	N/A	N/A
Mr. Karen Haslbeck	Head of HR	N/A	N/A	N/A
Dr. Daniel P. Bednarik	Sr. VP of Molecular Engineering & Protein Design	N/A	N/A	N/A
Dr. Robert Douglas Knight M.D.	Chief Medical Officer	N/A	N/A	1951
Mr. Chad Rubin	Sr. VP of Corp. Affairs	N/A	N/A	N/A
Dr. Jack A. Ragheb M.D., Ph.D.	Sr. VP of Translational Science	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

NexImmune, Inc.s ISS Governance QualityScore, Stand 1. September 2023, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.